Akari Therapeutics (AKTX) Shares Outstanding (2011 - 2026)

Akari Therapeutics (AKTX) has 8 years of Shares Outstanding (Entity) data on file, last reported at $9.3 million in Q4 2022.

• For the quarter ending Q4 2022, Shares Outstanding (Entity) rose 56.41% year-over-year to $9.3 million; the trailing twelve-month figure through Dec 2022 stood at $9.3 million (up 56.41% YoY), and the FY2022 full-year result was $9.3 million, up 56.41% from the prior year.
• Shares Outstanding (Entity) grew to $9.3 million in Q4 2022, from $5.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $9.3 million in Q4 2022 to a low of $2.0 million in Q4 2018.
• A 5-year average of $3.7 million and a median of $3.1 million in 2020 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) rose 15.84% in 2019 and soared 93.83% in 2020, its largest moves.
• Tracing AKTX's Shares Outstanding (Entity) over 5 years: stood at $2.0 million in 2018, then rose by 15.84% to $2.3 million in 2019, then soared by 72.53% to $3.9 million in 2020, then jumped by 50.67% to $5.9 million in 2021, then soared by 56.41% to $9.3 million in 2022.
• Business Quant data shows AKTX's Shares Outstanding (Entity) at $9.3 million in Q4 2022, $5.9 million in Q4 2021, and $3.9 million in Q4 2020.